Citigroup Begins Coverage on Danaher (NYSE:DHR)

Equities researchers at Citigroup started coverage on shares of Danaher (NYSE:DHR) in a report issued on Tuesday. The brokerage set a “buy” rating and a $230.00 price target on the conglomerate’s stock. Citigroup’s price objective would suggest a potential upside of 33.02% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Robert W. Baird lowered their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Morgan Stanley dropped their price target on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. The Goldman Sachs Group reduced their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 price objective on shares of Danaher in a research report on Tuesday, April 21st. Finally, Wolfe Research cut their target price on shares of Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $238.24.

Danaher Price Performance

Shares of DHR traded up $0.90 on Tuesday, reaching $172.90. The stock had a trading volume of 1,396,283 shares, compared to its average volume of 4,340,096. The firm has a market capitalization of $122.37 billion, a PE ratio of 33.44, a PEG ratio of 2.30 and a beta of 0.81. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average of $183.23 and a 200 day moving average of $208.40. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The company’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.88 EPS. Sell-side analysts expect that Danaher will post 8.43 EPS for the current year.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently bought and sold shares of the stock. Elevated Capital Advisors LLC purchased a new position in Danaher during the fourth quarter worth approximately $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Danaher during the 4th quarter worth $27,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Danaher by 71.6% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after buying an additional 53 shares during the period. JPL Wealth Management LLC purchased a new position in shares of Danaher in the 3rd quarter worth $25,000. Finally, Main Street Group LTD acquired a new position in Danaher in the first quarter valued at $25,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.